Servier and MiNA Therapeutics ink neurology pact
French pharma company Servier has entered into a research partnership with UK biotech MiNA Therapeutics to develop small activating RNA (saRNA) therapies for the treatment of neurological diseases.
Under the terms of the deal, MiNA will engage its saRNA platform to identify new potential treatments with the aim of restoring normal cell function in neurological disorders.
Meanwhile, Servier will be responsible for preclincial and clinical development of the lead candidates and will retain the rights for the commercialisation of any products resulting from the partnership.
Although details of the specifics of the deal are sparse, the companies disclosed that MiNA would receive an upfront payment and exclusivity fee for certain ‘targets of interest’.
MiNA will also be entitled to research and development, regulatory and commercial milestones and royalties.
Read more: http://www.pharmatimes.com/news/servier_and_mina_therapeutics_ink_neurology_pact_1361757
Under the terms of the deal, MiNA will engage its saRNA platform to identify new potential treatments with the aim of restoring normal cell function in neurological disorders.
Meanwhile, Servier will be responsible for preclincial and clinical development of the lead candidates and will retain the rights for the commercialisation of any products resulting from the partnership.
Although details of the specifics of the deal are sparse, the companies disclosed that MiNA would receive an upfront payment and exclusivity fee for certain ‘targets of interest’.
MiNA will also be entitled to research and development, regulatory and commercial milestones and royalties.
Read more: http://www.pharmatimes.com/news/servier_and_mina_therapeutics_ink_neurology_pact_1361757